For research use only. Not for therapeutic Use.
Tripelennamine is a widely used H1 antagonist, inhibiting PhIP glucuronidation with IC50 of 30 μM.<br>Tripelennamine is a substrate for a tertiary amine UDP-glucuronosyltransferases which catalyzes the formation of quaternary ammonium-linked glucuronides. Tripelennamine inhibits the glucuronidation of 2-amino-1-methyl-6-phenylimidazo[4,5-b] pyridine (PhIP) by a mixture of competitive and noncompetitive inhibition in both human and rabbit liver microsomes.<br>Tripelennamine HCl (i.v.) causes central nervous system (CNS) excitement in standing horses, and the horses became very alert, agitated, and uncomfortable, as indicated by their raising the head and tightening the neck muscles, excessive rapid movements of eyes and ears, biting, snorting, briskly swishing the tail, and stomping and pawing with front feet. Accordingly, hemoglobin concentration of standing horses increase significantly after Tripelennamine HCl treatment. Tripelennamine HCl (i.v.) significantly increases mixed venous blood O<sub>2</sub> tension and hemoglobin-O<sub>2</sub> saturation in standing horse, as well as arterial and mixed-venous blood O<sub>2</sub> contents, but the arterial-to-mixed-venous O<sub>2</sub> content gradient of standing horses is not significantly affected.
| Catalog Number | A001085 |
| CAS Number | 154-69-8 |
| Synonyms | Pyribenzamine HCl |
| Molecular Formula | C16H22ClN3 |
| Purity | ≥95% |
| Target | Neuronal Signaling |
| Solubility | Limited solubility |
| Storage | 3 years -20C powder |
